OPK's growth is fueled by Rayaldee's success and strategic partnerships. However, stiff competition and overdependence on its lead product are concerns.
Despite OPKO Health's (OPK) strength in the Diagnostics segment, its overall second-quarter results reflect soft performances.
OPKO Health (OPK) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.03 per share a year ago.
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock?